Three independently deleted regions at chromosome arm 16q in human prostate cancer:: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient

被引:41
作者
Elo, JP
Härkönen, P
Kyllönen, AP
Lukkarinen, O
Vihko, P
机构
[1] Oulu Univ, Bioctr, FIN-90220 Oulu, Finland
[2] Oulu Univ, WHO Collaborating Ctr Res Reprod Hlth, FIN-90220 Oulu, Finland
[3] Oulu Univ, Dept Pathol, FIN-90220 Oulu, Finland
[4] Oulu Univ, Dept Surg, FIN-90220 Oulu, Finland
[5] Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland
关键词
16q; loss of heterozygosity; prostate cancer; HSD17B2; 17HSD type 2;
D O I
10.1038/sj.bjc.6690025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of heterozygosity at chromosome arm 16q is a frequent event in human prostate cancer. In this study, loss of heterozygosity at 16q was studied in 44 prostate cancer patients exhibiting various clinical features. Fifteen polymorphic polymerase chain reaction (PCR) markers were used to identify the separately deleted areas and the findings were compared with clinicopathological variables and 5-year survival of the patients. The results indicated that there are at least three independently deleted regions at 16q. Allelic losses at the central and distal areas were associated significantly with aggressive behaviour of the disease (16q24.1-q24.2, P < 0.01, and 16q24.3-qter, P < 0.05), and the central area of deletion was further significantly associated with poorly differentiated tumour cells (P < 0.05) and with recurrent (P < 0.01) growth of the tumour. During the follow-up period, 28% of the patients initially with MO disease developed distant metastases. Of the patients showing allelic loss at 16q24.1-q24.2, distant metastasis were found in 45% during the 5-year follow-up period, and 31% of the patients showing loss at 16q21.1 also developed distant metastases. After the 5-year follow-up period, 14 (32%) of the patients remained alive, whereas 19 (43%) had died because of their prostate cancer. The overall survival rate of the patients showing allelic loss at 16q21.1 or 16q24.1-q24.2 was significantly lower than that of the patients with retained heterozygosity.
引用
收藏
页码:156 / 160
页数:5
相关论文
共 28 条
  • [1] DELETION MAPPING OF CHROMOSOME-8, CHROMOSOME-10, AND CHROMOSOME-16 IN HUMAN PROSTATIC-CARCINOMA
    BERGERHEIM, USR
    KUNIMI, K
    COLLINS, VP
    EKMAN, P
    [J]. GENES CHROMOSOMES & CANCER, 1991, 3 (03) : 215 - 220
  • [2] THE USE OF MULTIPLE-VARIABLES TO PREDICT RESPONSE TO ENDOCRINE THERAPY IN CARCINOMA OF THE PROSTATE - A PRELIMINARY-REPORT
    BRENDLER, CB
    ISAACS, JT
    FOLLANSBEE, AL
    WALSH, PC
    [J]. JOURNAL OF UROLOGY, 1984, 131 (04) : 694 - 700
  • [3] Canzian F, 1996, CANCER RES, V56, P3331
  • [4] ALLELIC LOSS OF CHROMOSOME-16Q AND CHROMOSOME-10Q IN HUMAN PROSTATE-CANCER
    CARTER, BS
    EWING, CM
    WARD, WS
    TREIGER, BF
    AALDERS, TW
    SCHALKEN, JA
    EPSTEIN, JI
    ISAACS, WB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) : 8751 - 8755
  • [5] Cher ML, 1996, CANCER RES, V56, P3091
  • [6] TNM CLASSIFICATION OF UROLOGICAL TUMORS IN 1988
    CHISHOLM, GD
    [J]. BRITISH JOURNAL OF UROLOGY, 1988, 62 (06): : 501 - 501
  • [7] Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts
    Delos, S
    Carsol, JL
    Ghazarossian, E
    Raynaud, JP
    Martin, PM
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 55 (3-4) : 375 - 383
  • [8] A comprehensive genetic map of the human genome based on 5,264 microsatellites
    Dib, C
    Faure, S
    Fizames, C
    Samson, D
    Drouot, N
    Vignal, A
    Millasseau, P
    Marc, S
    Hazan, J
    Seboun, E
    Lathrop, M
    Gyapay, G
    Morissette, J
    Weissenbach, J
    [J]. NATURE, 1996, 380 (6570) : 152 - 154
  • [9] DUROVIC L, 1995, HIST EPISTEMOLOGIE L, V17, P17
  • [10] Elo JP, 1997, CANCER RES, V57, P3356